Dr. Carlo is a co-founder of Adamis Pharmaceuticals Corporation and has served as its President and Chief Executive officer since October 2006. Dr. Carlo has extensive biotech research and development experience and is widely regarded as one of the “Founding Fathers” of the San Diego biotech industry. He was one of the original “Test Tube Cowboys” of Hybritech. He served as Vice President of Research and Development and Therapeutic Manufacturing at Hybritech Inc., which was acquired by Eli Lilly & Co in 1985. After the sale to Lilly, Dr. Carlo, along with Dr. Jonas Salk, James Glavin and Kevin Kimberland, founded The Immune Response Corporation, a public company, where he served in various capacities from Chief Scientific Officer, COO and President and Chief Executive Officer. He served as president of Telos Pharmaceuticals, a private biotechnology company, from 2003 to 2006. Dr. Carlo has extensive experience in the development of vaccines and biologics. Early in his career, as Director of Developmental and Basic Cellular Immunology and Director of Bacterial Vaccines and Immunology at Merck & Co., he oversaw research and product development for PNEUMOVAX (multi-valent polysaccharide vaccine), MENINGOVAX A, MENINGOVAX C, MENINGOVAX A-C, and H. influenzae type b, and also directed a multi-disciplinary task force whose goal was the development of novel adjuvants. At Hybritech, he managed a successful program to carry out research and development in the area of monoclonal antibody and cancer therapy. At The Immune Response Corporation, he established programs in Autoimmunity and HIV and led the product development in successful clinical trials. Dr. Carlo received a B.S. degree in Microbiology from Ohio State University and has a Ph.D. in Immunology and Medical Microbiology from Ohio State University. He is named on 23 patents and has authored over 225 articles and abstracts in the field of Immunology

Mr. Hopkins joined Adamis in April 2007 and has been Vice President, Finance and Chief Financial Officer since August 2007. From 2000 to 2004, he was an Executive Vice President and the Chief Financial Officer of Chatham Capital Corp. Mr. Hopkins served as Chief Financial Officer of Veritel Corp from 1999 and 2000, a biometric software company. He has also served as Chief Operating Officer for Circle Trust Company from 2004 to 2005. From 2005 until Mr. Hopkins joined Adamis in 2007, he consulted for Acumen Enterpises providing analysis and business plans for the various projects. From 1997 to 1999, Mr. Hopkins was Senior Vice President for Finance for the Mariner Post-Acute Network. Among his previous medical-related experience, he has served as Assistant Administrator of Finance for Kindred Hospitals; President and Chief Executive Officer of Doctors Hospital of Hyde Park; and Vice President of Accounting for Cancer Treatment Centers of America. Mr. Hopkins received a B.S. degree in Finance from Indiana State University and an M.B.A. from Lake Forest Graduate School of Management.

Mr. Marguglio is a co-founder of Adamis and has served as Vice President of Corporate Development and Investor Relations since June 2006. From 1996 to 2006, he has held various positions of Vice President with Citigroup Global Markets, Smith Barney and Merrill Lynch. Before entering the financial industry, from 1994 to 1996, he founded and ran two different startup companies, the latter of which he successfully sold to a Fortune 100 company. Mr. Marguglio began his career as a financial analyst. He received a degree in finance and management from the Hankamer School of Business at Baylor University.

Dr. Moll has close to 20 years of experience in both academic and industrial preclinical research and development in the areas of inflammation, immunology and cancer biology. As part of his work, Dr. Moll has gained extensive experience in the generation, production and use of biologics, including protein/Fc chimeras, antibodies and gene therapeutics. After concluding his diploma studies in Biochemistry at the Biocenter, University of Basel, Switzerland, Dr. Moll received his doctorate degree in Genetics and Biochemistry “With Honours” from the University of Vienna, Austria. Subsequent to his work with Boehringer Ingelheim and Sandoz (now Novartis) in Vienna, Austria, Dr. Moll served as Assistant Professor at the University of Muenster, Germany, before joining Cardion AG, a privately held German biotech company. At Cardion, (then Cardiogene) Dr. Moll was initially in charge of the company’s preclinical cardiovascular gene therapy program, before taking over the responsibility for Cardion’s immunology programs as Vice President of Immunology. In this function he supervised the research and preclinical development of several protein/Fc fusion proteins, including CRB-15, an antagonist IL-15/Fc fusion protein. In 2003, Roche Pharmaceuticals licensed this protein for clinical development in various autoimmune disease indications. Before joining the Adamis management team, Dr. Moll was responsible for all research and development activities at Telos Pharmaceuticals. Dr. Moll serves as Editor of the Journal of Immune Based Therapies and has been a member of the European Society of Gene Therapy, the North American Vascular Biology Organization, the American Association of Immunologists, and the American Society of Transplantation.

Dr. Maurizio Zanetti, M.D. is a Professor in the Department of Medicine of the University of California, San Diego and a member of the Moores UCSD Cancer Center. He received a Bachelor of Arts in Classical Studies from Lyceum Marcantonio Flaminio of Vittorio Veneto, Treviso, Italy. In 1974, he received his M.D. degree “summa cum laude” from the University of Padova Medical School, Italy. In 1977, he passed the Board in Nephrology at the University of Padova Medical School. He trained in Immunology at the University of Paris VI in Paris, France, the University of Connecticut Health Sciences in Farmington, CT, and The Scripps Research Institute in La Jolla, CA. Dr. Zanetti is a member of the American Association of Immunologists, the American Society for Clinical Investigation, the Clinical Immunology Society, the Henry Kunkel society, the Robert A. Good society, the Societe’ Francaise d’Immunologie, and the Societa' Italiana di Immunologia. He served as Associate Editor for the Journal of Immunology and Cellular Immunology. He served as member on NIH Study Sections since 1998. Prior to that, he served as a member for the Immunology review panel of the American Cancer Society. He served as ad hoc reviewer for the National Science Foundation and the Human Frontier Science Program, as well as for numerous scientific journals including: Nature, Nature Medicine, Nature Biotechnology, The Proceedings of the National Academy of Sciences, The Journal of Immunology, Blood, Cancer Research, and Clinical Cancer Research. He has been an invited speaker at over 60 national and international conferences and symposia, has published more than 150 articles on peer reviewed journal and contributed numerous book chapters. He was Editor of “The Molecular Basis of Pathology”, the book series “The Antibodies” and served as guest Editor of “Cancer Immunotherapy” for Springer Seminars of Immunopathology.

Mr. Aloi is President of Adamis Laboratories and a director of Adamis. He joined Adamis in connection with Adamis’ acquisition of Healthcare Ventures Group (Adamis Labs) in April 2007. He founded Aero Pharmaceuticals in 1997 and served as its President and CEO from 1997 to 2007. He developed Aero into a distributor of allergen extracts and related products, and managed Aero’s transition to a specialty pharmaceutical provider. From 1979 to 1997, before founding Aero, Mr. Aloi was Director of Sales and Marketing at Center Laboratories (a division of E. Merck), a manufacturer of allergenic extracts and prescription respiratory products, including the market leading epinephrine auto-injector. At Center Laboratories, Mr. Aloi oversaw a 50-person marketing group which included over 35 field sales representatives. His earlier positions within Center Laboratories included Sales Representative, Regional Manager, and National Sales Manager. Mr. Aloi has served in leadership and advisory roles for industry groups, including the Allergen Product Manufacturers Association, the American College of Allergy Asthma & Immunology, and the American Academy of Allergy Asthma & Immunology. Mr. Aloi received a B.A. in Political Science from Boston College in 1976.

Ms. Daniels joined Adamis in July 2009 as Vice President of Operations. She has over 30 years of experience in operational and engineering roles across diverse industries including: electronics, medical devices, contract manufacturing and pharmaceutical manufacturing. Prior to joining Adamis, Ms. Daniels served as President of Althea Technologies from 2007 to 2009. Althea Technologies is a contract manufacturer for the pharmaceutical industry. She also served as Sr. Director of operations and logistics for Vidacare, a medical device manufacturer from 2006 to 2007. Other roles have included President at Lambda Power 2003-2006, GM for Plexus Corporation and COO of Qtron which was sold to Plexus (1999-2003). Ms. Daniels has a BS degree from the University of Arizona.

Dr. Carlo is a co-founder of Adamis Pharmaceuticals Corporation and has served as its President and Chief Executive officer since October 2006. Dr. Carlo has extensive biotech research and development experience and is widely regarded as one of the “Founding Fathers” of the San Diego biotech industry. He was one of the original “Test Tube Cowboys” of Hybritech. He served as Vice President of Research and Development and Therapeutic Manufacturing at Hybritech Inc., which was acquired by Eli Lilly & Co in 1985. After the sale to Lilly, Dr. Carlo, along with Dr. Jonas Salk, James Glavin and Kevin Kimberland, founded The Immune Response Corporation, a public company, where he served in various capacities from Chief Scientific Officer, COO and President and Chief Executive Officer. He served as president of Telos Pharmaceuticals, a private biotechnology company, from 2003 to 2006. Dr. Carlo has extensive experience in the development of vaccines and biologics. Early in his career, as Director of Developmental and Basic Cellular Immunology and Director of Bacterial Vaccines and Immunology at Merck & Co., he oversaw research and product development for PNEUMOVAX (multi-valent polysaccharide vaccine), MENINGOVAX A, MENINGOVAX C, MENINGOVAX A-C, and H. influenzae type b, and also directed a multi-disciplinary task force whose goal was the development of novel adjuvants. At Hybritech, he managed a successful program to carry out research and development in the area of monoclonal antibody and cancer therapy. At The Immune Response Corporation, he established programs in Autoimmunity and HIV and led the product development in successful clinical trials. Dr. Carlo received a B.S. degree in Microbiology from Ohio State University and has a Ph.D. in Immunology and Medical Microbiology from Ohio State University. He is named on 23 patents and has authored over 225 articles and abstracts in the field of Immunology

Mr. Aloi is President of Adamis Laboratories and a director of Adamis. He joined Adamis in connection with Adamis’ acquisition of Healthcare Ventures Group (Adamis Labs) in April 2007. He founded Aero Pharmaceuticals in 1997 and served as its President and CEO from 1997 to 2007. He developed Aero into a distributor of allergen extracts and related products, and managed Aero’s transition to a specialty pharmaceutical provider. From 1979 to 1997, before founding Aero, Mr. Aloi was Director of Sales and Marketing at Center Laboratories (a division of E. Merck), a manufacturer of allergenic extracts and prescription respiratory products, including the market leading epinephrine auto-injector. At Center Laboratories, Mr. Aloi oversaw a 50-person marketing group which included over 35 field sales representatives. His earlier positions within Center Laboratories included Sales Representative, Regional Manager, and National Sales Manager. Mr. Aloi has served in leadership and advisory roles for industry groups, including the Allergen Product Manufacturers Association, the American College of Allergy Asthma & Immunology, and the American Academy of Allergy Asthma & Immunology. Mr. Aloi received a B.A. in Political Science from Boston College in 1976.

Mr. Marguglio is a co-founder of Adamis and has served as Vice President of Corporate Development and Investor Relations since June 2006. From 1996 to 2006, he has held various positions of Vice President with Citigroup Global Markets, Smith Barney and Merrill Lynch. Before entering the financial industry, from 1994 to 1996, he founded and ran two different startup companies, the latter of which he successfully sold to a Fortune 100 company. Mr. Marguglio began his career as a financial analyst. He received a degree in finance and management from the Hankamer School of Business at Baylor University.